Official Twitter for Genentech. See our community guidelines here: ow.ly/1sSw30lmszz
USA
- Tweets 7,819
- Following 225
- Followers 123,141
- Likes 2,320
#Breaking: The @US_FDA has approved our treatment for patients aged 2 and older with childhood-onset idiopathic nephrotic syndrome (INS). This is the first treatment option in 70 years to be approved for people living with this rare kidney disease. Learn more: gene.com/media/statements/ps…
6
1,474
#Breaking: Today we announced positive Phase III results of our investigational treatment in IgA nephropathy (IgAN), a rare and progressive kidney disease. Learn more: gene.com/media/press-release…
1
7
2,815
#Breaking: Positive Phase II results show our dual GLP-1/GIP receptor agonist demonstrated significant reductions in blood sugar and body weight in people with type 2 diabetes (#T2D) and #obesity or overweight.
Learn more: gene.com/media/press-release…
1
2
6
2,531
We’re investing in the science, infrastructure, and talent powering U.S. biotech leadership. Today, we opened the Roche Genentech Innovation Center Boston, a new hub tackling cardiovascular, renal, and metabolic (CVRM) diseases with AI and data: gene.com/media/press-release…
1
3
21
3,979
#Breaking: Our bispecific antibody combination met its primary endpoint for people living with relapsed or refractory follicular lymphoma. Read more: gene.com/media/press-release…
1
2
9
3,147
#Breaking: The @US_FDA has granted priority review for the first potential treatment for myelin oligodendrocyte glycoprotein antibody-associated disease (#MOGAD). Learn more: gene.com/media/press-release…
1
7
17
4,287
Today we announced an expansion of our Hillsboro, OR site with a new device fill-finish facility. This investment reflects our continued commitment to Hillsboro and the region's workforce as we build end-to-end U.S. drug manufacturing capabilities: gene.com/media/press-release…
3
2
3
2,803
Today marks a major milestone: the topping out of our first-ever East Coast manufacturing facility in Holly Springs, NC. The final beam placement reflects our progress and deep commitment to the region’s workforce, community, and long-term potential: gene.com/media/press-release…
3
3,056
#Breaking: The @US_FDA granted priority review to our treatment for primary membranous nephropathy (pMN), a chronic, idiopathic kidney condition.
If approved, it would be the first FDA-approved therapy specifically indicated to treat this disease. Read more: gene.com/media/press-release…
4
11
2,761
#Breaking: We are presenting data across our Alzheimer’s disease portfolio at #AAIC2026, highlighting our dedication to detect, slow and hopefully one day prevent this devastating disease. Learn more: gene.com/media/press-release…
1
5
2,290
#Breaking: New positive Phase III results demonstrate superiority of an investigational molecule over standard-of-care KRAS G12C inhibitors in the first global head-to-head study in KRAS G12C-mutant non-small cell lung cancer: gene.com/media/press-release…
1
4
11
6,525
#Breaking: The @US_FDA has granted priority review for our treatment for thyroid eye disease (TED), an autoimmune disease that can lead to facial disfigurement and vision threatening complications if left untreated. Learn more: gene.com/media/press-release…
1
2
8
2,445
#Breaking: @US_FDA accepted the supplemental Biologics License Application (sBLA) supporting a combination treatment for people living with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma: gene.com/media/press-release…
1
1
3
1,697
#Breaking: @US_FDA accepted our supplemental Biologics License Application (sBLA) and granted Priority Review for an investigational adjuvant combination regimen in a certain type of stage III colon cancer: gene.com/media/press-release…
2
2
6
2,416
#Breaking: @US_FDA accepted the New Drug Application, under Priority Review, for our investigational oral selective estrogen receptor degrader (SERD) as a treatment for adults with ER+, HER2-, early-stage breast cancer. Learn more: gene.com/media/press-release…
5
1,970
#Breaking: We are presenting data at the upcoming #ADASciSessions from our obesity portfolio, highlighting our differentiated approaches to addressing unmet needs for people living with #obesity. Learn more: gene.com/media/press-release…
4
1,662
#Breaking: We’re presenting new data across breast, lung, gastrointestinal, bladder and blood cancers at the American Society of Clinical Oncology (#ASCO26). Learn more about our efforts to transform cancer care: gene.com/media/press-release…
2
2
2,105
#Breaking: @US_FDA approved our immunotherapy as an adjuvant treatment option for adults with muscle-invasive bladder cancer (#MIBC) after surgery (cystectomy) who have circulating tumor DNA (ctDNA) molecular residual disease. Learn more: gene.com/media/press-release…
1
6
2,111
At the Association for Research in Vision and Ophthalmology Annual Meeting, we’re sharing key real-world, product and pipeline data from our ophthalmology portfolio. Learn more: gene.com/media/press-release… #ARVO2026
3
1,371